Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525094 | 1.00 | SLC7A5 (0.53) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8333097 | 0.98 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8333110 | 0.98 | SLC7A5 (0.54) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8020635 | 0.94 | SLC7A5 (0.59) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL8020641 | 0.94 | SLC7A5 (0.59) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| Phosphoric Acid SCHEMBL8003139 | 0.93 | SLC7A5 (0.49) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL321221 | 0.92 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL4279625 | 0.92 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL1938140 | 0.91 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL1938136 | 0.91 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765260-B1 | SANITIZING COMPOSITION AND METHOD OF PREPARATION | BROWN JAMES STEVEN (US) | 2017-08-09 | — | — | EP | claimed |
| EP-1765260-A2 | SANITIZING COMPOSITION AND METHOD OF PREPARATION | Brown, Steven J. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006085907-A2 | SANITIZING COMPOSITION AND METHOD OF PREPARATION | BROWN STEVEN J (US) | 2006-08-17 | — | — | WO | claimed |
| US-20050271595-A1 | Sanitizing composition and method of preparation | BROWN JAMES S | 2005-12-08 | — | — | US | claimed |
| US-20240237643-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | SYMRISE AG (DE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024147490-A1 | ORAL PREPARATION COMPRISING CHICORY FIBER OR CASSAVA STARCH | 주식회사 엘지생활건강 | 2024-07-11 | — | — | WO | disclosed |
| US-20240216248-A1 | MICROBIAL GLYCOLIPIDS | ANALYTICON DISCOVERY GMBH (DE) | 2024-07-04 | — | — | US | disclosed |
| EP-4387587-A1 | COMPOSITIONS | Symrise AG (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024110515-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2024-05-30 | — | — | WO | disclosed |
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | SYMRISE AG (DE) | 2024-05-30 | — | — | US | disclosed |
| WO-2024104546-A1 | A BLEND OF EMOLLIENTS | SYMRISE AG (DE) | 2024-05-23 | — | — | WO | disclosed |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | SYMRISE AG (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-0971686-B1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN | BEIERSDORF AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| EP-1303260-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | Pericor Science, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1203141-A1 | LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202706-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | Pericor Science, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-20020025303-A1 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A DERIVATIVE OF METHYLATED SILANOL AND A DERIVATIVE OF HYDROLYSED PLANT PROTEIN | BOOTS COMPANY, THE PLC (GB) | 2002-02-28 | — | — | US | disclosed |
| WO-2002007707-A2 | LINKAGE OF AGENTS USING MICROPARTICLES | PERICOR SCIENCE, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001006829-A2 | LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2001007009-A1 | LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE | PERICOR SCIENCE, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216248-A1 | MICROBIAL GLYCOLIPIDS | UGCG, SGMS1, GPR119 | SLC7A5 788/4885TAAR1 954/4885SLC6A2 3193/4885 |
| US-20240122816-A1 | ARTICLES FOR INDIRECT TRANSFER OF COSMETIC ACTIVES TO SKIN | CUTA, POLR1C, SLC16A7 | SLC7A5 81/4885TAAR1 4310/4885SLC6A2 1474/4885 |
| US-20240237643-A1 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | ZC3HAV1, SAMHD1, ZC3HAV1L | SLC7A5 4479/4885TAAR1 3983/4885SLC6A2 4760/4885 |
| US-20240173227-A1 | A FRAGRANCE MIXTURE CONTAINING ISOCITRONELLOL | IPO5, OR51E2, FDFT1 | SLC7A5 4723/4885TAAR1 2545/4885SLC6A2 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.